# Expert Assessment: TREM2/TYROBP as Therapeutic Target for Neurodegeneration
## Executive Summary
The hypothesis presents a mechanistically compelling pathway linking TREM2 loss-of-function to microglial senescence through lipid metabolism dysregulation. The target has strong genetic validation, is theoretically druggable, and has emerging tool compounds. However, significant translational gaps remain regarding the specific senescence endpoint and long-term safety.
---
## I. Target Druggability Assessment
### Druggable - Moderate to High Confidence
| Attribute | Assessment | Notes |
|-----------|------------|-------|
| **Target Class** | Type I transmembrane receptor | Extracellular ligand-binding domain accessible |
| **Molecular Access** | Feasible via biologics; challenging for small molecules | mAb approach most advanced |
| **CNS Penetration** | Major hurdle | Blood-brain barrier poses delivery challenge |
| **Genetic Validation** | Strong | R47H, R62H AD risk; loss-of-function variants in Nasu-Hakola disease |
**Druggability Rationale:**
- TREM2's extracellular domain (ECD) is a viable antibody target
- Ligand-binding sites (phosphatidylserine, APOE, lipoproteins) offer agonist opportunities
- TYROBP intracellular ITAM domain less accessible but targetable via orthogonal mechanisms
---
## II. Tool Compounds and Competitive Landscape
### Current Pipeline (Human Use)
| Compound | Developer | Stage | Mechanism | Notes |
|----------|-----------|-------|-----------|-------|
| **AZP2006** | AlzProtect | Phase 2 (PSP) | Increases TREM2 expression